Drugs interfering with apoptosis in breast cancer

Current Pharmaceutical Design

Volumn 17, Issue 3, 2011, Pages 272-283

  Grimm, Daniela ^a,b   Wehland, Markus ^b   Pietsch, Jessica ^b,c   Infanger, Manfred ^d   Bauer, Johann ^e  

^a AARHUS UNIVERSITY   (Denmark)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^e MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Apoptosis; BCL 2; Breast cancer; Fas; PARP inhibitors; TNF alpha; TRAIL

Indexed keywords

5 [5 (ETHYLPEROXY)PENTAN 2 YL] 6 METHYL 3 METHYLENE 2 OXO 2,3,3A,4,7,7A HEXAHYDROBENZOFURAN 4 YL 2 (6 METHOXYNAPHTHALEN 2 YL)PROPANOATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CARBOPLATIN; CASPASE INHIBITOR; CONATUMUMAB; CYCLOPHOSPHAMIDE; DICHLOROBENZYM CARBAMATE DERIVATIVE; DOCETAXEL; DOXORUBICIN; DROZITUMAB; DULANERMIN; ENTINOSTAT; INDOLONE DERIVATIVE; ISOSORBIDE; LEXATUMUMAB; MAPATUMUMAB; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PACLITAXEL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SPC 2996; TEMOZOLOMIDE; TIGATUZUMAB; TRA 8; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; Z VALYLALANYLASPARTIC ACID FLUOROMETHYLKETONE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; INTRACELLULAR SIGNALING; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TARGET CELL DESTRUCTION; THROMBOCYTOPENIA;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; DRUG DISCOVERY; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958192767     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795049723     Document Type: Review

References (116)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global healthconcern. Cancer Epidemiol 2009; 33: 315-8.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patternsof breast carcinomas distinguish tumour subclasses with clinicalimplications. PNAS 2001; 98(19): 10869-74.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes,and survival in the Carolina Breast cancer Study. JAMA.2006; 295(21): 2492-502.
4. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer - current status and future directions.Ann Oncol 2009; 20: 1913-27.
5. Metzger-Filho O, Vora T, Awada A. Management of metastaticHER2-positive breast cancer progression after adjuvant Trastuzumabtherapy - current evidence and future trends. Expert Opin InvestigDrugs 2010; Suppl 1: S31-S39.
6. Grimm D, Bauer J, Pietsch J, et al. Diagnostic and therapeutic useof membrane proteins in cancer cells. Curr Med Chem 2011; 18:176-90.
7. www.clinicaltrials.gov
8. Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D. Innovativestrategies in in vivo apoptosis imaging. Curr Med Chem 2008;15(2): 187-94.
9. Hong LZ, Zhao XY, Zhang HL. p53-mediated neuronal cell deathin ischemic brain injury. Neurosci Bull 2010; 26(3): 232-40.
10. Kossmehl P, Kurth E, Faramarzi S, et al. Mechanisms of apoptosisafter ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis 2006; 11(3): 347-58.
11. Infanger M, Kossmehl P, Shakibaei M, et al. Induction of threedimensionalassembly and increase in apoptosis of human endothelialcells by simulated microgravity: impact of vascular endothelialgrowth factor. Apoptosis; 11(5): 749-64.
12. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation.Science 1998; 281(5381): 1305-8.
13. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapyagainst Bcl-2-related proteins in breast cancer cells. Breast CancerRes 2005; 7: R940-52.
14. Moreira JN, Santos A, Simões S. Bcl-2-targeted antisense therapy(Oblimersen sodium): towards clinical reality. Rev Recent ClinTrials 2006; 1(3): 217-35.
15. Rom J, von Minckwitz G, Eiermann W, et al. Oblimersen combinedwith docetaxel, adriamycin and cyclophosphamide as neoadjuvantsystemic treatment in primary breast cancer: final resultsof a multicentric phase I study. Ann Oncol 2008; 19(10): 1698-705.
16. Rom J, von Minckwitz G, Marmé F, et al. Phase I study of apoptosisgene modulation with oblimersen within preoperative chemotherapyin patients with primary breast cancer. Ann Oncol. 2009;20(11): 1829-35.
17. Esteva FJ, Madden TL, Lammey J, et al. Phase I and pharmacokinetic(PK) study of oblimersen, a proapoptotic Bcl-2 targeting oligonucleotide,in combination with doxorubicin and docetaxel inmetastatic and locally advanced breast cancer (BC). Journal ofClinical Oncology 2004; ASCO Annual Meeting Proceedings(Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement),2004; 22: 3117.
18. Moulder SL, Symmans WF, Booser DJ, et al. Phase I/II study ofG3139 (Bcl-2 antisense oligonucleotide) in combination withdoxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008;14(23): 7909-16.
19. Mitchell C, Yacoub A, Hamed H, et al. Inhibition of MCL-1 inbreast cancer cells promotes cell death in vitro and in vivo. CancerBiol Ther 2010; 10(9): 903-17.
20. Wang J, Lenardo MJ. Roles of caspases in apoptosis, development,and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000; 113: 753-7.
21. Moretti L, Kim KW, Jung DK, Willey CD, Lu B. Radiosensitizationof solid tumors by Z-VAD, a pan-caspase inhibitor. Mol CancerTher 2009; 8(5): 1270-9.
22. Liu B, Han M, Sun RH, et al. ABL-N-induced apoptosis in humanbreast cancer cells is partially mediated by c-Jun NH2-terminalkinase activation. Breast Cancer Res 2010; 12(1): R9.
23. Dong Z, Zeitlin BD, Song W, et al. Level of endothelial cell apoptosisrequired for a significant decrease in microvessel density. ExpCell Res 2007; 313: 3645-57.
24. Nor JE, Hu Y, Song W, Spencer DM, Nunez G. Ablation of microvesselsin vivo upon dimerization of iCaspase-9. Gene Ther 2002; 9: 444-51.
25. Shariat SF, Desai S, Song W, et al. Adenovirus-mediated transferof inducible caspases: a novel death switch gene therapeutic approachto prostate cancer. Cancer Res 2001; 61: 2562-71.
26. Song W, Dong Z, Jin T, Mantellini MG, Núñez G, Nör JE. Cancergene therapy with iCaspase-9 transcriptionally targeted to tumorendothelial cells. Cancer Gene Ther 2008; 15: 667-75.
27. Jia LT, Zhang LH, Yu CJ, et al. Specific tumoricidal activity of asecreted proapoptotic protein consisting of HER2 antibody andconstitutively active caspase-3. Cancer Res 2003; 63: 3257-62.
28. Xu YM, Wang LF, Jia LT, et al. A caspase-6 and anti-humanepidermal growth factor receptor-2 (HER2) antibody chimericmolecule suppresses the growth of HER2-overexpressing tumors. JImmunol 2004; 173: 61-7.
29. Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteinsand prothymosin-alpha in a death regulatory pathway. Science 2003; 299: 223-26.
30. Nguyen JT, Wells JA. Direct activation of the apoptosis machineryas a mechanism to target cancer cells. Proc Natl Acad Sci USA 2003; 100: 7533-8.
31. Rahman M, Pumphrey JG, Lipkowitz S. The TRAIL to targetedtherapy of breast cancer. Adv Cancer Res 2009; 103: 43-73.
32. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity oftumor necrosis factor-related apoptosis-inducing ligand in vivo. NatMed 1999; 5: 157-63.
33. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab,a fully human agonistic monoclonal antibody which targetsand activates the TRAIL receptor-1, in patients with advancednon-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
34. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab(fully human monoclonal antibody to TRAIL-R1) in patientswith advanced solid malignancies. Clin Cancer Res 2008; 14:3450-55.
35. Wakelee HA, Patnaik A, Sikic BI, et al. Phase I and pharmacokineticstudy of lexatumumab (HGS-ETR2) given every 2 weeks inpatients with advanced solid tumors. Ann Oncol 2010; 21: 376-81.
36. Doi T, Murakami H, Ohtsu A, et al. Phase 1 study of conatumumab,a pro-apoptotic death receptor 5 agonist antibody, in Japanesepatients with advanced solid tumors. Cancer Chemother Pharmacol 2010; Dec 16. [Epub ahead of print]
37. Camidge DR, Herbst RS, Gordon MS, et al. A phase I safety andpharmacokinetic study of the death receptor 5 agonistic antibodyPRO95780 in patients with advanced malignancies. Clin CancerRes 2010; 16: 1256-63.
38. Zinonos I, Labrinidis A, Lee M, et al. Apomab, a fully humanagonistic antibody to DR5, exhibits potent antitumor activityagainst primary and metastatic breast cancer. Mol Cancer Ther 2009; 8: 2969-80.
39. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalationstudy of recombinant human Apo2L/TRAIL, a dual proapoptoticreceptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-46.
40. Lu M, Strohecker A, Chen F, et al. Aspirin sensitizes cancer cellsto TRAIL-induced apoptosis by reducing survivin levels. Clin CancerRes 2008; 14(10): 3168-76.
41. Stagg J, Sharkey J, Pommey S, et al. Antibodies targeted to TRAILreceptor-2 and ErbB-2 synergize in vivo and induce an antitumorimmune response. Proc Natl Acad Sci USA 2008; 105(42): 16254-9.
42. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance theapoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24: 4609-23.
43. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAILon apoptosis in human leukemia cells: involvement of both deathreceptor and mitochondrial pathways. Int J Mol Med 2005; 16:1125-38.
44. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAILresistantbreast cancer cells, inhibits angiogenesis and metastasis,and reverses epithelial-mesenchymal transition in vivo. Mol CancerTher 2010; 9: 3254-66.
45. Lee S, Yagita H, Sayers TJ, Celis E. Optimized combination therapyusing bortezomib, TRAIL and TLR agonists in establishedbreast tumors. Cancer Immunol Immunother 2010; 59(7): 1073-81.
46. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene,enhances TRAIL-induced apoptosis through the down-regulation ofcell survival proteins and up-regulation of death receptors. J BiolChem 2010; 285(15): 11498-507.
47. Qiu J, Xiao J, Han C, et al. Potentiation of tumor necrosis factoralpha-induced tumor cell apoptosis by a small molecule inhibitorfor anti-apoptotic protein hPEBP4. J Biol Chem 2010; 285(16):12241-7.
48. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activityof recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
49. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeatedtreatment with subtoxic doses of TRAIL induces resistance toapoptosis through its death receptors in MDA-MB-231 breast cancercells. Mol Cancer Res 2009; 7(11): 1835-44.
50. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL Agonistson Clinical Trials for Cancer Therapy: The Promises and the Challenges.Reviews on Recent Clinical Trials 2009; 4: 34-41.
51. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokineticstudy of lexatumumab in patients with advanced cancers. Clin CancerRes 2007; 13(20): 6187-94.
52. Yu W, Tiwary R, Li J, et al. α-TEA induces apoptosis of humanbreast cancer cells via activation of TRAIL/DR5 death receptorpathway. Mol Carcinog 2010; 49(11): 964-73.
53. Lahiry L, Saha B, Chakraborty J, et al. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammaryepithelial carcinoma cell apoptosis. Apoptosis 2008; 13: 771-81.
54. Lahiry L, Saha B, Chakraborty J, et al. Theaflavins targetFas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 2010; 31(2):259-68.
55. Way TD, Lee HH, Kao MC, Lin JK. Black tea polyphenoltheaflavins inhibit aromatase activity and attenuate tamoxifenresistance in HER2/neu-transfected human breast cancer cellsthrough tyrosine kinase suppression. Eur J Cancer 2004; 40: 2165-74.
56. Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizesMCF-7 breast cancer cells to doxorubicin-induced apoptosisthrough modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007; 6: 1031-8.
57. Nakayama J, Ogawa Y, Yoshigae Y, et al. A humanized antihumanFas antibody, R-125224, induces apoptosis in type I activatedlymphocytes but not in type II cells. Int Immunol 2006; 18:113-24.
58. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fasligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862-7.
59. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS.Intracellular Fas ligand expression causes Fas-mediated apoptosisin human prostate cancer cells resistant to monoclonal antibodyinducedapoptosis. Mol Ther 2000; 2: 348-58.
60. Liu Z, Liu R, Qiu J, et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumorresponse. Cell Mol Immunol 2009; 6: 167-74.
61. Eisele G, Roth P, Hasenbach K, et al. APO010, a synthetic hexamericCD95 ligand, induces human glioma cell death in vitro andin vivo. Neuro Oncol 2011; 13: 155-64.
62. Verbrugge I, Wissink EH, Rooswinkel RW, et al. Combiningradiotherapy with APO010 in cancer treatment. Clin Cancer Res 2009; 15: 2031-8.
63. Papenfuss K, Cordier SM, Walczak H. Death receptors as targetsfor anti-cancer therapy. J Cell Mol Med 2008; 12: 2566-85.
64. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. JBiol 2009; 8: 85.
65. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potentialtarget for the therapy of solid tumours. Lancet Oncol 2003; 4:565-73.
66. Eggermont AM, ten Hagen TL. Isolated limb perfusion for extremitysoft-tissue sarcomas, in-transit metastases, and other unresectabletumors: credits, debits, and future perspectives. Curr OncolRep 2001; 3: 359-67.
67. Shibata H, Yoshioka Y, Ikemizu S, et al. Functionalization oftumor necrosis factor-alpha using phage display technique and PEGylationimproves its antitumor therapeutic window. Clin CancerRes 2004; 10(24): 8293-300.
68. Chen B, Cao S, Zhang Y, et al. A novel peptide (GX1) homing togastric cancer vasculature inhibits angiogenesis and cooperateswith TNF alpha in anti-tumor therapy. BMC Cell Biol 2009; 10:63.
69. Gerspach J, Pfizenmaier K, Wajant H. Improving TNF as a cancertherapeutic: tailor-made TNF fusion proteins with conserved antitumoractivity and reduced systemic side effects. Biofactors 2009;35: 364-72.
70. Gerspach J, Wajant H, Pfizenmaier K. Death ligands designed tokill: development and application of targeted cancer therapeuticsbased on proapoptotic TNF family ligands. Results Probl Cell Differ 2009; 49:241-73.: 241-73.
71. Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade Biologic:preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factoralpha gene. Cancer Gene Ther 2002; 9: 951-57.
72. Weichselbaum RR, Kufe D. Translation of the radio- and chemoinducibleTNFerade vector to the treatment of human cancers. CancerGene Ther 2009; 16: 609-19.
73. Jung M, Dimtchev A, Velena A, Dritschilo A. Combining radiationtherapy with interstitial radiation-inducible TNF-alpha expressionfor locoregional cancer treatment. Cancer Gene Ther 2011; 18:189-95.
74. Wiman KG. Strategies for therapeutic targeting of the p53 pathwayin cancer. Cell Death Differ 2006; 13: 921-26.
75. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-8.
76. Shangary S, Qin D, McEachern D, et al. Temporal activation ofp53 by a specific MDM2 inhibitor is selectively toxic to tumorsand leads to complete tumor growth inhibition. Proc Natl Acad SciUSA 2008; 105: 3933-8.
77. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakeningguardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9: 862-73.
78. Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growthof breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009; 35: 1015-23.
79. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivatesmutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-88.
80. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, WilhelmMT. PRIMA-1(MET)/APR-246 targets mutant forms of p53 familymembers p63 and p73. Oncogene 2010; 29: 6442-51.
81. Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM. p53-Reactivating small molecules induce apoptosis and enhancechemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 2011; 16: 67-74.
82. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptoticevents induced by caspase-8 and cytochrome c by direct inhibitionof distinct caspases EMBO J 1998; 17: 2215-23.
83. Sohn DM, Kim SY, Baek, MJ, et al. Expression of survivin andclinical correlation in patients with breast cancer. Biomed Pharmacother 2006; 60: 289-92.
84. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulationof X-linked inhibitor of apoptosis (XIAP) increases resistanceto radiation induced cell death. Oncogene 2000; 19: 4174-7.
85. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of Xlinkedinhibitor of apoptosis protein induces apoptosis in chemoresistanthuman ovarian cancer cells. Cancer Res 2000; 60: 5659-66.
86. Carter BZ, Mak DH, Morris SJ, et al. XIAP antisense oligonucleotide(AEG35156) achieves target knockdown and induces apoptosispreferentially in CD34(+)38 (-) cells in a phase 1/2 study of patientswith relapsed/refractory AML. Apoptosis 2011; 16: 67-74.
87. Dean E, Jodrell D, Connolly K, et al. Phase I trial of AEG35156administered as a 7-day and 3-day continuous intravenous infusionin patients with advanced refractory cancer. J Clin Oncol 2009; 27:1660-6.
88. Lacasse EC, Kandimalla ER, Winocour P, et al. Application ofXIAP antisense to cancer and other proliferative disorders: developmentof AEG35156/ GEM640. Ann N Y Acad Sci 2005; 1058:215-34.
89. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinicalcharacterization of AEG35156/GEM 640, a second-generation antisenseoligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 2006; 12(17): 5231-41.
90. Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial ofAEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotidecombined with idarubicin and cytarabine in patientswith relapsed or primary refractory acute myeloid leukemia. J ClinOncol 2009; 27: 4741-6.
91. Tamm I. AEG-35156, an antisense oligonucleotide against Xlinkedinhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs 2008; 9: 638-46.
92. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial proteinthat promotes cytochrome c-dependent caspase activation by eliminatingIAP inhibition. Cell 2000; 102: 33-42.
93. Sun H, Nikolovska-Coleska Z, Yang CY, et al. Design of smallmoleculepeptidic and nonpeptidic Smac mimetics. Acc Chem Res 2008; 41: 1264-77.
94. Wang J, Zeng F, Wang L, Zhu Z, Jiang G. Synthetic Smac peptideenhances chemo-sensitivity of bladder cancer cells. J HuazhongUniv Sci Technolog Med Sci 2008; 28: 304-7.
95. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, HarranPG. A small molecule Smac mimic potentiates TRAIL- andTNFalpha-mediated cell death. Science 2004; 305: 1471-4.
96. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonistsof the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-26.
97. Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists:a patent review. Expert Opin Ther Pat 2010; 20: 251-67.
98. Dean E, Jodrell D, Connolly K, et al. Phase I trial of AEG35156administered as a 7-day and 3-day continuous intravenous infusionin patients with advanced refractory cancer. J Clin Oncol 2009;27(10): 1660-6.
99. Pal SK, Childs BH, Pegram M. Triple negative breast cancer:unmet medical needs. Breast Cancer Res Treat. 2011; 125: 627-36.
100. Soldatenkov VA, Smulson M. Poly(ADP-ribose)polymerase inDNA damage response pathway: Implications for radiation oncology.Int J Cancer (Radiat Oncol Inves) 2000; 90: 59-67.
101. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance ofapoptosis. Int Rev Cytol 1980; 68: 251-306.
102. Kaufman SH, Desnoyers S, Ottaviano Y, Davidson NE, PoirierGG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase:an early marker of chemotherapy-induced apoptosis. CancerRes 1993; 53: 3976-85.
103. Soldatenkov VA, Prasad S, Notario V, Dritschillo A. Radiationinducedapoptosis of Ewing's sarcoma cells: DNA fragmentationand proteolysis of poly(ADP-ribose) polymerase. Cancer Res 1995;55: 4240-2.
104. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally activepoly(ADP-ribose) polymerase inhibitor that potentiates DNAdamagingagents in preclinical tumor models. Clin Cancer Res 2007; 13(9): 2728-37.
105. Telli ML, Ford JM. PARP inhibitors in breast cancer. Clin AdvHematol Oncol 2010; 8(9): 629-35.
106. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-34.
107. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymeraseinhibitor olaparib in patients with BRCA1 or BRCA2 mutationsand advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235-44.
108. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumorsthat will respond PARP inhibitors? A phase II correlative study ofolaparib in advanced serous ovarian cancer and triple-negativebreast cancer J Clin Oncol 2010; 28: 233s.
109. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADPribose)polymerase inhibitor olaparib in patients with BRCA1 orBRCA2 mutations and recurrent ovarian cancer: a proof-of-concepttrial. Lancet 2010; 376(9737): 245-51.
110. Dent RA, Lindeman GJ, Clemons M, et al. Safety and efficacy ofthe oral PARP inhibitor olaparib (AZD2281) in combination withpaclitaxel for the first- or second-line treatment of patients withmetastatic triple-negative breast cancer: Results from the safety cohortof a phase I/II multicenter trial J Clin Oncol 2010; 28: 118s.
111. O'Shaughnessy J, Osborne C, Pippen J (2009) Final results of arandomized phase II study demonstrating efficacy and safety ofBSI-201, a poly (ADP-ribose) polymerase (PARP) inhibitor, incombination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) (Abstract no. 3122). Presentedat the 32nd Annual San Antonio Breast Cancer Symposium, SanAntonio, TX, December 9-13, 2009. Available at
112. http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_998.
113. Ossovskaya V, Li L, Broude EV, Lim C, Roninson IB, Bradley C, Sherman B (2009) BSI-201 enhances the activity of multipleclasses of cytotoxic agents and irradiation in triple-negative breastcancer (Abstract no. 5552). Presented at the 2009 American Associationfor Cancer Research 100th Annual Meeting, Denver, Co,April 18-22, 2009. Available at http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={A98A01B0-1623-4F71-99C7-FCE19F299C1F}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EEDC51FDFC6C15}&SKey={CCA05FCE-642E-4E26-AD12-29C831335BE1}.
114. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of thePARP inhibitor veliparib (ABT888) and temozolomide for metastaticbreast cancer. J Clin Oncol 2010; 28: 15s (suppl; abstr 1019)
115. Annunziata CM, O'Shaughnessy J. Poly (adp-ribose) polymerase asa novel therapeutic target in cancer. Clin Cancer Res 2010; 16(18):4517-26.
116. Grimm D, Bauer J, Schoenberger J. Blockade of neoangiogenesis,a new and promising technique to control the growth of malignanttumors and their metastases. Curr Vasc Pharmacol 2009; 7(3): 347-57.